samedan logo
 
 
 
spacer
home > ebr > Spring 2021
PUBLICATIONS

European Biopharmaceutical Review

ebr
Spring 2021

   
Text
PDF
bullet
CAR T Cell Therapy
Autologous, Allogeneic CAR T, and the New Frontiers of CAR NK Immunotherapy Products

Claudia Benati, Giulia Mancini, Stanley Prince, Marian L McKee, and Frederic Girard at Eurofins Biopharma Product Testing

Fighting cancer could be supported by the development and continued improvement in T cell and NK cell immunotherapy. As this complex area of work continues to evolve, the chance to find the next generation of cancer treatments improves
 
view
download pdf
Droplet Digital PCR for Safe and Effective CAR T Cell Therapies

Mark White at Bio-Rad

ddPCR can quantify transgene copy numbers more precisely than standard qPCR and reduce risk for patients, but how else can it support CAR T cell production?
 
view
download pdf
A Look into Leukopaks

Stephanie Nickles Thielemann and Andrew Winner at Lonza discuss the future of immunology and cell therapy, looking at how using cryopreserved leukopaks can alleviate several key research challenges
 
view
download pdf
bullet
Next-Generation Vaccines
Expediting Next-Generation Vaccine Development Using Advanced Analytical Methods

As Sartorius expands on its impressive portfolio, the company explores how the COVID-19 pandemic has brought to the fore novel analytical methods to ensure speed and efficacy throughout the rollout proces
 
view
download pdf
Beyond Cold

Dr Alex Esmon at Thermo Fisher Scientific

Vaccines have fundamentally changed with innovative mRNA and viral vector technologies driving their development. These new types of vaccines have unique cold storage requirements, which standard refrigerators and freezers cannot meet. Instead, ultra-low temperature freezers are needed to support vaccine storage
 
view
download pdf
A Challenge of Pandemic Proportions

Dr Steve Cutler, CEO of ICON, reveals what it was like running one of the biggest vaccine trials ever, and how it proved the value of partnership, and the key role of technology
 
view
download pdf
bullet
Cell Culture
Endotoxins – The Unwanted Contaminants in Biomaterials for Regenerative Medicines

Elien Gevaert, Principle Scientist at Rousselot Biomedical, talks about these disrupters of in vitroand in vivo cell growth and how they can stifle research and delay lab to clinic translation
 
view
download pdf
The Green Shoots of Tomorrow’s Cell Therapies

Thomas Marx and Dr Boris Greber at RheinCell Therapeutics GmbH

The potential of induced pluripotent stem cells as starting materials for novel advanced therapies, and the importance of innovation for the next generation
 
view
download pdf
Culture Shock: The Impact of Cell Culture-Based Technology in a New World

Anastassia Tselikova, Justin Field, and Omid Taghavian at FUJIFILM Irvine Scientific

Biotechnology has changed the scope of medicine in recent years. The potential of cell therapy is infinite, and the industry is now realising that the horizon of possibility is theirs for the taking

 
view
download pdf
Defining Cell Culture Conditions to Drive Cell Identity and Scalability in Cell Therapy

Dr Aida Moreno-Moral and Dr David Anderson at Mogrify

Using epigenetically predicted factors to mimic in vivo microenvironments and systematically define in vitro culture conditions for optimal cell maintenance and differentiation
 
view
download pdf
bullet
Features
Optimising Technical Transfers

Vladas Algirdas Bumelis, Prof., André Markmann, PhD, and Dominic Chow, PhD, at Northway Biotech offer insight into the challenges of tech transfers, and how the process can be improved

 
view
download pdf
The Next Big Thing in Sequencing Is Likely to Be Very Small

Paul Lomax at SPT Labtech

Next-generation sequencing is the heartbeat of modern genomics. The growth in the variety of techniques and applications is matched by the year-on-year cost reductions with the advent of the $100 genome now a matter of when rather than if
 
view
download pdf
Presenting the Fluidity One-W Serum

At Fluidic Analytics, we have developed a new instrument that enables comprehensive profiling of protein-protein interactions, such as the antibody response to SARS-CoV-2, based on affinity – a crucial characteristic of protein interactions that traditional tests cannot easily quantify
 
view
download pdf
Building Connective Tissue into Fine Chemical Markets

Gilles Cottier, Ed Roullard, Varun Vijay Rao, and Keith Wilkinson at Aceto

For a pharmaceutical company, choosing suppliers and partners is an extremely important decision, and there are three key considerations that should be kept in mind when making this choice
 
view
download pdf
Streamlining Biotech R&D

Dr Lukas Neutsch at ZHAW

What are the technical and conceptual requirements for taking research-oriented labs and production facilities to the cutting-edge standard of connectivity and holistic data exploitation?
 
view
download pdf
COVID-19 Highlights the Value of Drug Repurposing and Why We Should Continue

Pete Buckman at Medidata

What can be learned from the whirlwind of repurposed drug trials for COVID-19, and how can repurposing help in future?
 
view
download pdf
 
   
spacer


Published quarterly in
January, April,
July, and October

News and Press Releases

Survey Finds Industry Taking Action to Address Challenges from Rapid Move to Decentralized Trials Amid COVID-19

Sponsors and contract research organizations (CROs) are accelerating digital transformation to advance toward patient-centric, paperless, and decentralized trials, according to the Digital Clinical Trials Survey Report conducted by Veeva Systems (NYSE: VEEV).
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement